|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.63 USD | -1.46% |
|
-5.89% | +68.48% |
| 05/12 | Cvs Health generates over $474 billion in 2024 U.S. economic impact, supporting communities throughout the United States | RE |
| 05/12 | Bernstein Adjusts CVS Health Price Target to $86 From $77 | MT |
| Capitalization | 9.6TCr 8.25TCr 7.73TCr 7.21TCr 13TCr 8,64100Cr 14TCr 90TCr 35TCr 4,08100Cr 36TCr 35TCr 14,92100Cr | P/E ratio 2025 * |
152x | P/E ratio 2026 * | 13.4x |
|---|---|---|---|---|---|
| Enterprise value | 15TCr 13TCr 12TCr 12TCr 21TCr 13,86100Cr 23TCr 1,45100Cr 56TCr 6,54600Cr 58TCr 57TCr 23,93600Cr | EV / Sales 2025 * |
0.39x | EV / Sales 2026 * | 0.36x |
| Free-Float |
70.66% | Yield 2025 * |
3.64% | Yield 2026 * | 3.82% |
Last Transcript: CVS Health Corporation
| 1 day | -1.46% | ||
| 1 week | -5.89% | ||
| Current month | -5.89% | ||
| 1 month | -3.85% | ||
| 3 months | +2.51% | ||
| 6 months | +18.95% | ||
| Current year | +68.48% |
| 1 week | 74.14 |  | 81.06 |
| 1 month | 74.14 | | 81.72 |
| Current year | 44.11 | | 85.15 |
| 1 year | 43.56 | | 85.15 |
| 3 years | 43.56 | | 104.83 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 61 | 17/10/2024 |
Prem Shah
PSD | President | 45 | 06/11/2024 |
Brian Newman
DFI | Director of Finance/CFO | 56 | 12/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 73 | 01/03/2007 |
Anne Finucane
BRD | Director/Board Member | 72 | 20/01/2011 |
| Director/Board Member | 70 | 05/03/2015 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 3.92% | 26 M€ | +11.73% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.46% | -5.89% | +36.79% | -25.26% | 9.6TCr | |
| -0.20% | -4.25% | +52.21% | +105.69% | 11TCr | |
| -0.60% | +0.82% | +41.73% | +82.14% | 3.12TCr | |
| +1.04% | +3.35% | -12.51% | +18.76% | 2.34TCr | |
| -1.18% | -3.87% | +11.10% | +10.35% | 2.14TCr | |
| -0.91% | -3.53% | +15.99% | +22.51% | 2.03TCr | |
| -1.01% | -3.15% | +51.14% | +379.89% | 1.85TCr | |
| -7.00% | -5.43% | +60.95% | +52.49% | 1.8TCr | |
| +0.21% | -5.15% | +18.98% | +80.60% | 1.44TCr | |
| +0.07% | -2.93% | -12.40% | +34.23% | 1.34TCr | |
| Average | -1.13% | -2.86% | +26.40% | +76.14% | 3.68TCr | |
| Weighted average by Cap. | -0.94% | -3.62% | +35.50% | +61.39% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 40TCr 34TCr 32TCr 30TCr 55TCr 35,90900Cr 60TCr 3,75800Cr 1,45100Cr 16,96000Cr 1,49800Cr 1,46600Cr 62,01100Cr | 42TCr 36TCr 34TCr 31TCr 58TCr 37,64900Cr 63TCr 3,94000Cr 1,52100Cr 17,78100Cr 1,57000Cr 1,53700Cr 65,01500Cr |
| Net income | -21Cr -18Cr -17Cr -15Cr -29Cr -1.85TCr -31Cr -193.83Cr -75Cr -874.7Cr -77Cr -76Cr -3.2TCr | 722.89Cr 621.4Cr 582.12Cr 542.57Cr 1TCr 65TCr 1.09TCr 6.81TCr 2.63TCr 31TCr 2.71TCr 2.66TCr 1,12300Cr |
| Net Debt | 5.8TCr 4.99TCr 4.67TCr 4.35TCr 8.04TCr 5,22000Cr 8.75TCr 55TCr 21TCr 2,46600Cr 22TCr 21TCr 9,01500Cr | 5.28TCr 4.54TCr 4.25TCr 3.96TCr 7.32TCr 4,75200Cr 7.96TCr 50TCr 19TCr 2,24400Cr 20TCr 19TCr 8,20500Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/25/05 | 75.63 $ | -1.46% | 77,68,387 |
| 04/25/04 | 76.75 $ | +2.33% | 88,72,740 |
| 03/25/03 | 75.00 $ | -3.38% | 81,64,509 |
| 02/25/02 | 77.62 $ | -1.87% | 77,00,857 |
| 01/25/01 | 79.10 $ | -1.57% | 67,54,424 |
Delayed Quote Nyse, December 06, 2025 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition